Luca G Guidotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11701488/publications.pdf

Version: 2024-02-01

82 papers

11,170 citations

53 h-index 79 g-index

85 all docs 85 docs citations

85 times ranked 10541 citing authors

#	Article	IF	CITATIONS
1	Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. Immunity, 1996, 4, 25-36.	14.3	1,065
2	Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponse. Annual Review of Immunology, 2001, 19, 65-91.	21.8	896
3	IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 23-61.	22.4	669
4	Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo. Journal of Experimental Medicine, 2000, 192, 921-930.	8.5	560
5	Immune Pathogenesis of Hepatocellular Carcinoma. Journal of Experimental Medicine, 1998, 188, 341-350.	8.5	354
6	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
7	Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nature Medicine, 2005, 11, 1167-1169.	30.7	311
8	Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature, 2010, 465, 1079-1083.	27.8	309
9	Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells. Cell, 2015, 161, 486-500.	28.9	271
10	Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	16.8	267
11	Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2165-72.	7.1	267
12	To kill or to cure: options in host defense against viral infection. Current Opinion in Immunology, 1996, 8, 478-483.	5.5	257
13	Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. Journal of Virology, 2000, 74, 2255-2264.	3.4	238
14	Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2000, 74, 4165-4173.	3.4	226
15	Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 2001, 194, 1755-1766.	8.5	225
16	A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14913-14918.	7.1	219
17	Immunobiology and pathogenesis of hepatitis B virus infection. Nature Reviews Immunology, 2022, 22, 19-32.	22.7	199
18	Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins. Journal of Virology, 2005, 79, 3016-3027.	3.4	194

#	Article	IF	Citations
19	Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11181-11186.	7.1	183
20	In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood, 2007, 109, 2797-2805.	1.4	168
21	Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Virology, 2002, 76, 10702-10707.	3.4	166
22	Noncytopathic Clearance of Lymphocytic Choriomeningitis Virus from the Hepatocyte. Journal of Experimental Medicine, 1999, 189, 1555-1564.	8.5	141
23	Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice. Journal of Virology, 1998, 72, 2630-2637.	3.4	138
24	Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature, 2019, 574, 200-205.	27.8	135
25	Host–virus interactions in hepatitis B virus infection. Current Opinion in Immunology, 2015, 36, 61-66.	5.5	133
26	Cytokine-Mediated Control of Viral Infections. Virology, 2000, 273, 221-227.	2.4	123
27	Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. Journal of Leukocyte Biology, 2007, 81, 100-107.	3.3	120
28	Platelets prevent IFN- \hat{l} ±/ \hat{l}^2 -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 629-634.	7.1	119
29	Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Experimental Medicine, 2000, 191, 1247-1252.	8.5	117
30	The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Research, 1998, 18, 79-92.	2.9	115
31	Interferon-Regulated Pathways That Control Hepatitis B Virus Replication in Transgenic Mice. Journal of Virology, 2002, 76, 2617-2621.	3.4	112
32	Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13717-13722.	7.1	110
33	Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice. Journal of Immunology, 2002, 169, 5188-5195.	0.8	109
34	Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes. Journal of Virology, 2003, 77, 1227-1236.	3.4	108
35	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	8.2	106
36	Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor 1î±-Null Hepatitis B Virus Transgenic Mice. Journal of Virology, 2001, 75, 2900-2911.	3.4	103

#	Article	IF	Citations
37	Cutting Edge: Inhibition of Hepatitis B Virus Replication by Activated NK T Cells Does Not Require Inflammatory Cell Recruitment to the Liver. Journal of Immunology, 2001, 167, 6701-6705.	0.8	102
38	Kupffer Cells Hasten Resolution of Liver Immunopathology in Mouse Models of Viral Hepatitis. PLoS Pathogens, 2011, 7, e1002061.	4.7	96
39	Inflammatory monocytes hinder antiviral B cell responses. Science Immunology, 2016, 1, .	11.9	93
40	Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice. Journal of Virology, 1999, 73, 474-481.	3.4	91
41	Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help. Journal of Immunology, 2012, 188, 3217-3222.	0.8	90
42	HBV pathogenesis in animal models: Recent advances on the role of platelets. Journal of Hepatology, 2007, 46, 719-726.	3.7	84
43	Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1135-1138.	3.7	82
44	Nkx2-5+Islet1+ Mesenchymal Precursors Generate Distinct Spleen Stromal Cell Subsets and Participate in Restoring Stromal Network Integrity. Immunity, 2013, 38, 782-791.	14.3	82
45	La Autoantigen Specifically Recognizes a Predicted Stem-Loop in Hepatitis B Virus RNA. Journal of Virology, 1999, 73, 5767-5776.	3.4	79
46	Cytokine-induced viral purging â€" role in viral pathogenesis. Current Opinion in Microbiology, 1999, 2, 388-391.	5.1	73
47	Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice. Journal of Immunology, 2001, 166, 1389-1397.	0.8	73
48	Identification of a Kupffer cell subset capable of reverting the TÂcell dysfunction induced by hepatocellular priming. Immunity, 2021, 54, 2089-2100.e8.	14.3	73
49	Bone marrow as an alternative site for islet transplantation. Blood, 2009, 114, 4566-4574.	1.4	72
50	Role of CCL2/MCP-1 in Islet Transplantation. Cell Transplantation, 2010, 19, 1031-1046.	2.5	69
51	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	8.2	63
52	Host–Virus Interactions during Malaria Infection in Hepatitis B Virus Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 529-536.	8.5	61
53	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2022, 7, .	11.9	61
54	Antiplatelet Drug Therapy Moderates Immune-Mediated Liver Disease and Inhibits Viral Clearance in Mice Infected with a Replication-Deficient Adenovirus. Vaccine Journal, 2007, 14, 1532-1535.	3.1	56

#	Article	IF	Citations
55	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Molecular Therapy, 2022, 30, 311-326.	8.2	54
56	Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site. Journal of Virology, 2001, 75, 6874-6883.	3.4	53
57	In Vivo Regulation of Hepatitis B Virus Replication by Peroxisome Proliferators. Journal of Virology, 1999, 73, 10377-10386.	3.4	51
58	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. Journal of Hepatology, 2017, 67, 543-548.	3.7	48
59	The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine, 2002, 20, A80-A82.	3.8	47
60	Inhibition of Hepatitis B Virus Replication during Schistosoma mansoni Infection in Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 289-294.	8.5	39
61	Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. Cell Reports, 2013, 5, 323-330.	6.4	39
62	Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. Journal of Experimental Medicine, 2020, 217, .	8.5	31
63	Effector CD8 T cell trafficking within the liver. Molecular Immunology, 2013, 55, 94-99.	2.2	29
64	$\langle scp \rangle IFN \langle scp \rangle \hat{l} \pm gene/cell$ therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Molecular Medicine, 2016, 8, 155-170.	6.9	29
65	Mouse Models of Hepatitis B Virus Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021477.	6.2	23
66	In Vivo Flow Mapping in Complex Vessel Networks by Single Image Correlation. Scientific Reports, 2014, 4, 7341.	3.3	21
67	Group 1 ILCs regulate T cell–mediated liver immunopathology by controlling local IL-2 availability. Science Immunology, 2022, 7, eabi6112.	11.9	18
68	Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology, 2006, 1, 189-196.	1.8	17
69	On the role of platelets in the pathogenesis of viral hepatitis. Journal of Hepatology, 2009, 51, 599-600.	3.7	16
70	Thymic Tolerance to Only One Viral Protein Reduces Lymphocytic Choriomeningitis Virus-Induced Immunopathology and Increases Survival in Perforin-Deficient Mice. Journal of Virology, 1999, 73, 5918-5925.	3.4	16
71	Pathogenâ€specific Bâ€cell receptors drive chronic lymphocytic leukemia by lightâ€chainâ€dependent crossâ€reaction with autoantigens. EMBO Molecular Medicine, 2017, 9, 1482-1490.	6.9	15
72	Naive HIV/HCV-Coinfected Patients Have Higher Intrahepatic Pro-Inflammatory Cytokines than Coinfected Patients Treated with Antiretroviral Therapy. Antiviral Therapy, 2006, 11, 385-389.	1.0	13

#	Article	IF	CITATIONS
73	Microcirculation in the murine liver: a computational fluid dynamic model based on 3D reconstruction from in vivo microscopy. Journal of Biomechanics, 2017, 63, 125-134.	2.1	12
74	The COP9 signalosome is a repressor of replicative stress responses and polyploidization in the regenerating liver. Hepatology, 2014, 59, 2331-2343.	7.3	6
75	Immunological insights in the treatment of chronic hepatitis B. Current Opinion in Immunology, 2022, 77, 102207.	5 . 5	5
76	Developing a cure for chronic hepatitis B requires a fresh approach. Nature, 2022, 603, S49-S49.	27.8	3
77	Lowâ€dose aspirin reduces the risk of HBVâ€associated HCC even when administered shortâ€term: Too good to be true?. Hepatology, 2022, 76, 300-302.	7.3	2
78	Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. Science Signaling, 2022, 15, eabb0384.	3.6	2
79	Pathogenesis of Hepatitis B Virus inTransgenic Mice. , 2005, 25, 25-32.		1
80	Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?. Gastroenterology, 2020, 159, 1988-1990.	1.3	1
81	Protective and Pathogenic T Cell Responses to Virus Infections. , 2016, , 318-323.		1
82	Hepatitis B Virus Immunopathogenesis. Molecular and Translational Medicine, 2016, , 79-93.	0.4	O